Drugs / Hanferon
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01194037 | Jun → Nov 2011 | chronic hepatitis C virus infection | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hanferon | “Subcutaneous Hanferon™ in Combination With Ribavirin” NCT01194037 ↗ |
| Modality | Protein / enzyme biologic | “recombinant variant of interferon-alpha 2b” NCT01194037 ↗ |
| Route | Subcutaneous | “SC, Weekly” NCT01194037 ↗ |